Precision Health Clinical Trials
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Condition: Uveal Melanoma
Intervention: Biological: Blood sampling
Sponsor: Institut Curie
Recruiting
Intervention: Biological: Blood sampling
Sponsor: Institut Curie
Recruiting
For more information, visit the Study URL.
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Conditions: Brain Cancer; Brain Tumor; Spine Cancer; Spine Tumor; Neoplasm
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
For more information, visit the Study URL.
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer; Melanoma; Gynecological Cancer; Genitourinary Cancer; Pancreatobiliary Cancer; Gastrointestinal Cancer; Head and Neck Cancer; Rare Cancer; Unknown Primary Cancer
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
For more information, visit the Study URL.
Vaginal and Urinary Microbiome Trial
Conditions: Atrophic Vaginitis; Menopause; Recurrent Urinary Tract Infections
Interventions: Drug: Premarin vaginal cream; Drug: Apricot kernel oil
Sponsor: University of Louisville
Recruiting
Interventions: Drug: Premarin vaginal cream; Drug: Apricot kernel oil
Sponsor: University of Louisville
Recruiting
For more information, visit the Study URL.
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
Conditions: Obesity; Alzheimer's Disease
Intervention: Procedure: Blood sample
Sponsor: Central Hospital, Nancy, France
Not yet recruiting
Intervention: Procedure: Blood sample
Sponsor: Central Hospital, Nancy, France
Not yet recruiting
For more information, visit the Study URL.
The Drug Rediscovery Protocol (DRUP Trial)
Conditions: Cancer; Tumors; Neoplasm; Neoplasia
Interventions: Drug: Panitumumab; Drug: Olaparib; Drug: Dabrafenib; Drug: Nilotinib; Drug: Trametinib; Drug: Erlotinib; Drug: Trastuzumab and Pertuzumab (combination treatment); Drug: Vemurafenib and Cobimetinib (combination treatment); Drug: Vismodegib; Drug: Regorafenib; Drug: Nivolumab; Drug: Afatinib; Drug: Dabrafenib and trametinib; Drug: Ribociclib; Drug: Lenvatinib; Drug: Pembrolizumab; Drug: Durvalumab; Drug: Rucaparib; Drug: Axitinib; Drug: Palbociclib; Drug: Crizotinib; Drug: Sunitinib; Drug: Cabozantinib; Drug: Abemaciclib; Drug: Alectinib; Drug: Atezolizumab and Bevacizumab; Drug: Ipilimumab and nivolumab; Drug: Entrectinib; Drug: Talazoparib; Drug: Dacomitinib; Drug: Lorlatinib; Drug: Erdafitinib; Drug: Alpelisib
Sponsors: The Netherlands Cancer Institute; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Novartis; Roche Pharma AG; Merck Sharp & Dohme LLC; Boehringer Ingelheim; Ipsen; Eisai Inc.; Pfizer; Clovis Oncology, Inc.; Eli Lilly and Company; Janssen, LP
Recruiting
Interventions: Drug: Panitumumab; Drug: Olaparib; Drug: Dabrafenib; Drug: Nilotinib; Drug: Trametinib; Drug: Erlotinib; Drug: Trastuzumab and Pertuzumab (combination treatment); Drug: Vemurafenib and Cobimetinib (combination treatment); Drug: Vismodegib; Drug: Regorafenib; Drug: Nivolumab; Drug: Afatinib; Drug: Dabrafenib and trametinib; Drug: Ribociclib; Drug: Lenvatinib; Drug: Pembrolizumab; Drug: Durvalumab; Drug: Rucaparib; Drug: Axitinib; Drug: Palbociclib; Drug: Crizotinib; Drug: Sunitinib; Drug: Cabozantinib; Drug: Abemaciclib; Drug: Alectinib; Drug: Atezolizumab and Bevacizumab; Drug: Ipilimumab and nivolumab; Drug: Entrectinib; Drug: Talazoparib; Drug: Dacomitinib; Drug: Lorlatinib; Drug: Erdafitinib; Drug: Alpelisib
Sponsors: The Netherlands Cancer Institute; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Novartis; Roche Pharma AG; Merck Sharp & Dohme LLC; Boehringer Ingelheim; Ipsen; Eisai Inc.; Pfizer; Clovis Oncology, Inc.; Eli Lilly and Company; Janssen, LP
Recruiting
For more information, visit the Study URL.
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: Inivata; Vector Oncology
Recruiting
Intervention:
Sponsors: Inivata; Vector Oncology
Recruiting
For more information, visit the Study URL.
Salt-sensitive Hypertension Study in Lantian County
Condition: Hypertension
Intervention: Dietary Supplement: salt
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting
Intervention: Dietary Supplement: salt
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting
For more information, visit the Study URL.
Glucose Metabolism in Sickle Cell Disease
Conditions: Sickle Cell Disease; Diabetes Mellitus
Intervention:
Sponsor: University of Illinois at Chicago
Recruiting
Intervention:
Sponsor: University of Illinois at Chicago
Recruiting
For more information, visit the Study URL.
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
Conditions: Carcinoma; Non-small-cell Lung Cancer; Lung Neoplasms
Intervention:
Sponsors: Peking University People's Hospital; San Valley Biotechnology Incorporated
Not yet recruiting
Intervention:
Sponsors: Peking University People's Hospital; San Valley Biotechnology Incorporated
Not yet recruiting
For more information, visit the Study URL.